Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTD1KRKO)

• DOT Name: Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1)
• Synonyms: Cytoplasmic dynein heavy chain 1; Dynein heavy chain, cytosolic
• Gene Name: DYNC1H1
• Related Disease:
  Autosomal dominant childhood-onset proximal spinal muscular atrophy without contractures
  Charcot-Marie-Tooth disease type 3
  Intellectual disability, autosomal dominant 13
  Obsolete neuronopathy, distal hereditary motor
  Tuberculosis
  Advanced cancer
  Arthritis
  Arthrogryposis
  Charcot marie tooth disease
  Charcot-Marie-Tooth disease axonal type 2O
  Chronic granulomatous disease
  Colorectal carcinoma
  Congenital myopathy
  Distal hereditary motor neuropathy
  Estrogen-receptor positive breast cancer
  Head-neck squamous cell carcinoma
  Hepatitis B virus infection
  Hereditary motor and sensory neuropathy
  Hereditary spastic paraplegia
  Isolated congenital microcephaly
  Lyme disease
  Macular corneal dystrophy
  Medullary thyroid gland carcinoma
  Microlissencephaly
  Neoplasm
  Obstructive sleep apnea
  Polycystic kidney disease
  Primary cutaneous peripheral T-cell lymphoma not otherwise specified
  Spinal muscular atrophy
  Syphilis
  Thyroid gland papillary carcinoma
  Autosomal dominant non-syndromic intellectual disability
  Adult lymphoma
  Autism
  Hepatitis C virus infection
  Hepatocellular carcinoma
  Hyperglycemia
  Hyperinsulinemia
  Intellectual disability
  Lymphoma
  Pediatric lymphoma
  Rett syndrome
  Schistosomiasis
  Toxoplasmosis
• UniProt ID: DYHC1_HUMAN
• PDB ID: 5NUG; 5OWO; 6F1T; 6F1U; 6F1V; 6F1Y; 6F38; 6F3A; 7Z8F; 7Z8G; 7Z8H; 7Z8I; 7Z8J; 7Z8K; 7Z8L; 8DYU; 8DYV; 8FCY; 8FD6; 8FDT; 8FDU
• Pfam ID: PF12774 ; PF12775 ; PF12780 ; PF12781 ; PF18198 ; PF08385 ; PF08393 ; PF17852 ; PF18199 ; PF03028 ; PF12777
• Sequence:
  MSEPGGGGGEDGSAGLEVSAVQNVADVSVLQKHLRKLVPLLLEDGGEAPAALEAALEEKS
  ALEQMRKFLSDPQVHTVLVERSTLKEDVGDEGEEEKEFISYNINIDIHYGVKSNSLAFIK
  RTPVIDADKPVSSQLRVLTLSEDSPYETLHSFISNAVAPFFKSYIRESGKADRDGDKMAP
  SVEKKIAELEMGLLHLQQNIEIPEISLPIHPMITNVAKQCYERGEKPKVTDFGDKVEDPT
  FLNQLQSGVNRWIREIQKVTKLDRDPASGTALQEISFWLNLERALYRIQEKRESPEVLLT
  LDILKHGKRFHATVSFDTDTGLKQALETVNDYNPLMKDFPLNDLLSATELDKIRQALVAI
  FTHLRKIRNTKYPIQRALRLVEAISRDLSSQLLKVLGTRKLMHVAYEEFEKVMVACFEVF
  QTWDDEYEKLQVLLRDIVKRKREENLKMVWRINPAHRKLQARLDQMRKFRRQHEQLRAVI
  VRVLRPQVTAVAQQNQGEVPEPQDMKVAEVLFDAADANAIEEVNLAYENVKEVDGLDVSK
  EGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSRFNALFVRPHIRGA
  IREYQTQLIQRVKDDIESLHDKFKVQYPQSQACKMSHVRDLPPVSGSIIWAKQIDRQLTA
  YMKRVEDVLGKGWENHVEGQKLKQDGDSFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTI
  ESTRVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGFRVPLAIVNKAHQANQLYPFAIS
  LIESVRTYERTCEKVEERNTISLLVAGLKKEVQALIAEGIALVWESYKLDPYVQRLAETV
  FNFQEKVDDLLIIEEKIDLEVRSLETCMYDHKTFSEILNRVQKAVDDLNLHSYSNLPIWV
  NKLDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDAPQVSHKPGGEPKIKNVVH
  ELRITNQVIYLNPPIEECRYKLYQEMFAWKMVVLSLPRIQSQRYQVGVHYELTEEEKFYR
  NALTRMPDGPVALEESYSAVMGIVSEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQ
  ALLVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHKEVLSKFGQMLGSNMT
  EFHSQISKSRQELEQHSVDTASTSDAVTFITYVQSLKRKIKQFEKQVELYRNGQRLLEKQ
  RFQFPPSWLYIDNIEGEWGAFNDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTTDLLTD
  WEKTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALELTDTGLLSGSEERVQ
  VALEELQDLKGVWSELSKVWEQIDQMKEQPWVSVQPRKLRQNLDALLNQLKSFPARLRQY
  ASYEFVQRLLKGYMKINMLVIELKSEALKDRHWKQLMKRLHVNWVVSELTLGQIWDVDLQ
  KNEAIVKDVLLVAQGEMALEEFLKQIREVWNTYELDLVNYQNKCRLIRGWDDLFNKVKEH
  INSVSAMKLSPYYKVFEEDALSWEDKLNRIMALFDVWIDVQRRWVYLEGIFTGSADIKHL
  LPVETQRFQSISTEFLALMKKVSKSPLVMDVLNIQGVQRSLERLADLLGKIQKALGEYLE
  RERSSFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKKMFAGVSSIILNEDNSVVLGISSRE
  GEEVMFKTPVSITEHPKINEWLTLVEKEMRVTLAKLLAESVTEVEIFGKATSIDPNTYIT
  WIDKYQAQLVVLSAQIAWSENVETALSSMGGGGDAAPLHSVLSNVEVTLNVLADSVLMEQ
  PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFYFDPKQTDVLQQLSIQ
  MANAKFNYGFEYLGVQDKLVQTPLTDRCYLTMTQALEARLGGSPFGPAGTGKTESVKALG
  HQLGRFVLVFNCDETFDFQAMGRIFVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQE
  ALREHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPGYAGRSNLPDNLKKLFRSLA
  MTKPDRQLIAQVMLYSQGFRTAEVLANKIVPFFKLCDEQLSSQSHYDFGLRALKSVLVSA
  GNVKRERIQKIKREKEERGEAVDEGEIAENLPEQEILIQSVCETMVPKLVAEDIPLLFSL
  LSDVFPGVQYHRGEMTALREELKKVCQEMYLTYGDGEEVGGMWVEKVLQLYQITQINHGL
  MMVGPSGSGKSMAWRVLLKALERLEGVEGVAHIIDPKAISKDHLYGTLDPNTREWTDGLF
  THVLRKIIDSVRGELQKRQWIVFDGDVDPEWVENLNSVLDDNKLLTLPNGERLSLPPNVR
  IMFEVQDLKYATLATVSRCGMVWFSEDVLSTDMIFNNFLARLRSIPLDEGEDEAQRRRKG
  KEDEGEEAASPMLQIQRDAATIMQPYFTSNGLVTKALEHAFQLEHIMDLTRLRCLGSLFS
  MLHQACRNVAQYNANHPDFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRR
  ITTVPLPTAPNIPIIDYEVSISGEWSPWQAKVPQIEVETHKVAAPDVVVPTLDTVRHEAL
  LYTWLAEHKPLVLCGPPGSGKTMTLFSALRALPDMEVVGLNFSSATTPELLLKTFDHYCE
  YRRTPNGVVLAPVQLGKWLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGGFYRTSDQTW
  VKLERIQFVGACNPPTDPGRKPLSHRFLRHVPVVYVDYPGPASLTQIYGTFNRAMLRLIP
  SLRTYAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMTRWVRGIFEALRPLETLPVEG
  LIRIWAHEALRLFQDRLVEDEERRWTDENIDTVALKHFPNIDREKAMSRPILYSNWLSKD
  YIPVDQEELRDYVKARLKVFYEEELDVPLVLFNEVLDHVLRIDRIFRQPQGHLLLIGVSG
  AGKTTLSRFVAWMNGLSVYQIKVHRKYTGEDFDEDLRTVLRRSGCKNEKIAFIMDESNVL
  DSGFLERMNTLLANGEVPGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIR
  NLHVVFTMNPSSEGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGKEFTSKMDLEKPNY
  IVPDYMPVVYDKLPQPPSHREAIVNSCVFVHQTLHQANARLAKRGGRTMAITPRHYLDFI
  NHYANLFHEKRSELEEQQMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDKL
  KKMVKDQQEAEKKKVMSQEIQEQLHKQQEVIADKQMSVKEDLDKVEPAVIEAQNAVKSIK
  KQHLVEVRSMANPPAAVKLALESICLLLGESTTDWKQIRSIIMRENFIPTIVNFSAEEIS
  DAIREKMKKNYMSNPSYNYEIVNRASLACGPMVKWAIAQLNYADMLKRVEPLRNELQKLE
  DDAKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAAVEAKVNRSTALLK
  SLSAERERWEKTSETFKNQMSTIAGDCLLSAAFIAYAGYFDQQMRQNLFTTWSHHLQQAN
  IQFRTDIARTEYLSNADERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFI
  MNEYKDRKITRTSFLDDAFRKNLESALRFGNPLLVQDVESYDPVLNPVLNREVRRTGGRV
  LITLGDQDIDLSPSFVIFLSTRDPTVEFPPDLCSRVTFVNFTVTRSSLQSQCLNEVLKAE
  RPDVDEKRSDLLKLQGEFQLRLRQLEKSLLQALNEVKGRILDDDTIITTLENLKREAAEV
  TRKVEETDIVMQEVETVSQQYLPLSTACSSIYFTMESLKQIHFLYQYSLQFFLDIYHNVL
  YENPNLKGVTDHTQRLSIITKDLFQVAFNRVARGMLHQDHITFAMLLARIKLKGTVGEPT
  YDAEFQHFLRGNEIVLSAGSTPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIW
  LDSSSPEQTVPYLWSEETPATPIGQAIHRLLLIQAFRPDRLLAMAHMFVSTNLGESFMSI
  MEQPLDLTHIVGTEVKPNTPVLMCSVPGYDASGHVEDLAAEQNTQITSIAIGSAEGFNQA
  DKAINTAVKSGRWVMLKNVHLAPGWLMQLEKKLHSLQPHACFRLFLTMEINPKVPVNLLR
  AGRIFVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYFLLAWFHAIIQERLRYAPLG
  WSKKYEFGESDLRSACDTVDTWLDDTAKGRQNISPDKIPWSALKTLMAQSIYGGRVDNEF
  DQRLLNTFLERLFTTRSFDSEFKLACKVDGHKDIQMPDGIRREEFVQWVELLPDTQTPSW
  LGLPNNAERVLLTTQGVDMISKMLKMQMLEDEDDLAYAETEKKTRTDSTSDGRPAWMRTL
  HTTASNWLHLIPQTLSHLKRTVENIKDPLFRFFEREVKMGAKLLQDVRQDLADVVQVCEG
  KKKQTNYLRTLINELVKGILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISLAAASGG
  AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVTTSQGATLDACSFGV
  TGLKLQGATCNNNKLSLSNAISTALPLTQLRWVKQTNTEKKASVVTLPVYLNFTRADLIF
  TVDFEIATKEDPRSFYERGVAVLCTE
• Function: Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Plays a role in mitotic spindle assembly and metaphase plate congression.
• KEGG Pathway:
  Phagosome (hsa04145)
  Motor proteins (hsa04814)
  Vasopressin-regulated water reabsorption (hsa04962)
  Salmonella infection (hsa05132)
• Reactome Pathway:
  MHC class II antigen presentation (R-HSA-2132295)
  Separation of Sister Chromatids (R-HSA-2467813)
  Resolution of Sister Chromatid Cohesion (R-HSA-2500257)
  Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942)
  HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand (R-HSA-3371497)
  Loss of Nlp from mitotic centrosomes (R-HSA-380259)
  Recruitment of mitotic centrosome proteins and complexes (R-HSA-380270)
  Loss of proteins required for interphase microtubule organization from the centrosome (R-HSA-380284)
  Recruitment of NuMA to mitotic centrosomes (R-HSA-380320)
  Anchoring of the basal body to the plasma membrane (R-HSA-5620912)
  RHO GTPases Activate Formins (R-HSA-5663220)
  Neutrophil degranulation (R-HSA-6798695)
  COPI-mediated anterograde transport (R-HSA-6807878)
  COPI-independent Golgi-to-ER retrograde traffic (R-HSA-6811436)
  Mitotic Prometaphase (R-HSA-68877)
  AURKA Activation by TPX2 (R-HSA-8854518)
  HCMV Early Events (R-HSA-9609690)
  Aggrephagy (R-HSA-9646399)
  EML4 and NUDC in mitotic spindle formation (R-HSA-9648025)
  Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444)

Molecular Interaction Atlas (MIA) of This DOT

44 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Autosomal dominant childhood-onset proximal spinal muscular atrophy without contractures	DISHY37K	Definitive	Autosomal dominant	[1]
Charcot-Marie-Tooth disease type 3	DIS6DQK1	Definitive	Biomarker	[2]
Intellectual disability, autosomal dominant 13	DISPQGMN	Definitive	Autosomal dominant	[3]
Obsolete neuronopathy, distal hereditary motor	DIS0A1HJ	Definitive	Autosomal dominant	[4]
Tuberculosis	DIS2YIMD	Definitive	Biomarker	[5]
Advanced cancer	DISAT1Z9	Strong	Genetic Variation	[6]
Arthritis	DIST1YEL	Strong	Biomarker	[7]
Arthrogryposis	DISC81CM	Strong	Biomarker	[1]
Charcot marie tooth disease	DIS3BT2L	Strong	Genetic Variation	[2]
Charcot-Marie-Tooth disease axonal type 2O	DISM3VHO	Strong	Autosomal dominant	[8]
Chronic granulomatous disease	DIS9ZR24	Strong	Genetic Variation	[9]
Colorectal carcinoma	DIS5PYL0	Strong	Biomarker	[6]
Congenital myopathy	DISLSK9G	Strong	Genetic Variation	[1]
Distal hereditary motor neuropathy	DISGS2ID	Strong	Genetic Variation	[10]
Estrogen-receptor positive breast cancer	DIS1H502	Strong	Biomarker	[11]
Head-neck squamous cell carcinoma	DISF7P24	Strong	Genetic Variation	[12]
Hepatitis B virus infection	DISLQ2XY	Strong	Biomarker	[13]
Hereditary motor and sensory neuropathy	DISR0X2K	Strong	Biomarker	[2]
Hereditary spastic paraplegia	DISGZQV1	Strong	Genetic Variation	[14]
Isolated congenital microcephaly	DISUXHZ6	Strong	Biomarker	[15]
Lyme disease	DISO70G5	Strong	Biomarker	[7]
Macular corneal dystrophy	DISOLD0H	Strong	Genetic Variation	[15]
Medullary thyroid gland carcinoma	DISHBL3K	Strong	Biomarker	[16]
Microlissencephaly	DISUCKNT	Strong	Biomarker	[15]
Neoplasm	DISZKGEW	Strong	Genetic Variation	[12]
Obstructive sleep apnea	DIS0SVD1	Strong	Genetic Variation	[17]
Polycystic kidney disease	DISWS3UY	Strong	Genetic Variation	[18]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	DIS5OHQF	Strong	Biomarker	[19]
Spinal muscular atrophy	DISTLKOB	Strong	Genetic Variation	[20]
Syphilis	DISJ73BS	Strong	Biomarker	[7]
Thyroid gland papillary carcinoma	DIS48YMM	Strong	Biomarker	[21]
Autosomal dominant non-syndromic intellectual disability	DISD6L06	Supportive	Autosomal dominant	[22]
Adult lymphoma	DISK8IZR	Limited	Genetic Variation	[23]
Autism	DISV4V1Z	Limited	Genetic Variation	[24]
Hepatitis C virus infection	DISQ0M8R	Limited	Biomarker	[25]
Hepatocellular carcinoma	DIS0J828	Limited	Biomarker	[13]
Hyperglycemia	DIS0BZB5	Limited	Genetic Variation	[26]
Hyperinsulinemia	DISIDWT6	Limited	Genetic Variation	[26]
Intellectual disability	DISMBNXP	Limited	Genetic Variation	[27]
Lymphoma	DISN6V4S	Limited	Genetic Variation	[23]
Pediatric lymphoma	DIS51BK2	Limited	Genetic Variation	[23]
Rett syndrome	DISGG5UV	Limited	Biomarker	[24]
Schistosomiasis	DIS6PD44	Limited	Biomarker	[28]
Toxoplasmosis	DISYP8FH	Limited	Biomarker	[29]

16 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[30]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[31]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[32]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[33]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[34]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[36]
Vorinostat	DMWMPD4	Approved	Vorinostat decreases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[37]
Selenium	DM25CGV	Approved	Selenium increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[38]
Menadione	DMSJDTY	Approved	Menadione affects the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[39]
Gemcitabine	DMSE3I7	Approved	Gemcitabine decreases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[41]
Urethane	DM7NSI0	Phase 4	Urethane increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[42]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[38]
Torcetrapib	DMDHYM7	Discontinued in Phase 2	Torcetrapib increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[46]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[47]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde decreases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[48]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[49]

5 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Arsenic	DMTL2Y1	Approved	Arsenic affects the methylation of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[35]
Fulvestrant	DM0YZC6	Approved	Fulvestrant increases the methylation of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[40]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[43]
TAK-243	DM4GKV2	Phase 1	TAK-243 decreases the sumoylation of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[44]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 affects the phosphorylation of Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1).	[45]

References

• [1] Expanding the phenotypic spectrum associated with mutations of DYNC1H1. Neuromuscul Disord. 2017 Jul;27(7):607-615. doi: 10.1016/j.nmd.2017.04.011. Epub 2017 May 5.
• [2] A novel mouse model carrying a human cytoplasmic dynein mutation shows motor behavior deficits consistent with Charcot-Marie-Tooth type 2O disease.Sci Rep. 2018 Jan 29;8(1):1739. doi: 10.1038/s41598-018-20081-1.
• [3] Novel dynein DYNC1H1 neck and motor domain mutations link distal spinal muscular atrophy and abnormal cortical development. Hum Mutat. 2014 Mar;35(3):298-302. doi: 10.1002/humu.22491. Epub 2014 Jan 3.
• [4] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [5] Proteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis.Clin Proteomics. 2017 Nov 2;14:36. doi: 10.1186/s12014-017-9171-z. eCollection 2017.
• [6] Computational prediction and analysis of deleterious cancer associated missense mutations in DYNC1H1.Mol Cell Probes. 2017 Aug;34:21-29. doi: 10.1016/j.mcp.2017.04.004. Epub 2017 Apr 26.
• [7] A chromosomal Borrelia burgdorferi gene encodes a 22-kilodalton lipoprotein, P22, that is serologically recognized in Lyme disease.J Clin Microbiol. 1994 Apr;32(4):876-83. doi: 10.1128/jcm.32.4.876-883.1994.
• [8] Dominant spinal muscular atrophy with lower extremity predominance: linkage to 14q32. Neurology. 2010 Aug 10;75(6):539-46. doi: 10.1212/WNL.0b013e3181ec800c.
• [9] Therapeutic effects of proteoliposomes on X-linked chronic granulomatous disease: proof of concept using macrophages differentiated from patient-specific induced pluripotent stem cells.Int J Nanomedicine. 2017 Mar 20;12:2161-2177. doi: 10.2147/IJN.S128611. eCollection 2017.
• [10] Exome Sequencing Identifies De Novo DYNC1H1 Mutations Associated With Distal Spinal Muscular Atrophy and Malformations of Cortical Development.J Child Neurol. 2017 Mar;32(4):379-386. doi: 10.1177/0883073816683083. Epub 2016 Dec 20.
• [11] Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.J Nanobiotechnology. 2018 Feb 20;16(1):17. doi: 10.1186/s12951-018-0345-2.
• [12] Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.Cancer Genet Cytogenet. 2007 Jul 15;176(2):100-6. doi: 10.1016/j.cancergencyto.2007.04.003.
• [13] Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.J Virol. 2019 Jun 14;93(13):e00196-19. doi: 10.1128/JVI.00196-19. Print 2019 Jul 1.
• [14] Mutation analysis of genes within the dynactin complex in a cohort of hereditary peripheral neuropathies.Clin Genet. 2016 Aug;90(2):127-33. doi: 10.1111/cge.12712. Epub 2016 Feb 16.
• [15] Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat Genet. 2013 Jun;45(6):639-47. doi: 10.1038/ng.2613. Epub 2013 Apr 21.
• [16] Site-directed chromosome rearrangements in skin fibroblasts from persons carrying genes for hereditary neoplasms.Cancer Res. 1980 Dec;40(12):4796-803.
• [17] Cognitive function in prepubertal children with obstructive sleep apnea: a modifying role for NADPH oxidase p22 subunit gene polymorphisms?.Antioxid Redox Signal. 2012 Jan 15;16(2):171-7. doi: 10.1089/ars.2011.4189. Epub 2011 Oct 12.
• [18] Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth in Pkd1-Deficient Mice.J Am Soc Nephrol. 2018 Sep;29(9):2310-2325. doi: 10.1681/ASN.2018010074. Epub 2018 Jul 24.
• [19] ins(6;11) in a case of peripheral T-cell lymphoma.Cancer Genet Cytogenet. 1987 Aug;27(2):367-9. doi: 10.1016/0165-4608(87)90021-5.
• [20] DYNC1H1 gene methylation correlates with severity of spinal muscular atrophy.Ann Hum Genet. 2019 Mar;83(2):73-81. doi: 10.1111/ahg.12288. Epub 2018 Sep 24.
• [21] Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.Oncotarget. 2017 Feb 7;8(6):9597-9607. doi: 10.18632/oncotarget.14162.
• [22] Mutations in DYNC1H1 cause severe intellectual disability with neuronal migration defects. J Med Genet. 2012 Mar;49(3):179-83. doi: 10.1136/jmedgenet-2011-100542.
• [23] Structural abnormalities of the X chromosome in non-Hodgkin's lymphoma.Leukemia. 1993 Jun;7(6):848-52.
• [24] A "new" chromosome marker common to the Rett syndrome and infantile autism? The frequency of fragile sites at X p22 in 81 children with infantile autism, childhood psychosis and the Rett syndrome.Brain Dev. 1985;7(3):365-7. doi: 10.1016/s0387-7604(85)80046-2.
• [25] Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus.Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4641-5. doi: 10.1073/pnas.88.11.4641.
• [26] Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age.Neurobiol Dis. 2013 Oct;58:220-30. doi: 10.1016/j.nbd.2013.05.015. Epub 2013 Jun 4.
• [27] A missense mutation in DYNC1H1 gene causing spinal muscular atrophy - Lower extremity, dominant.Neurol Neurochir Pol. 2018 Mar;52(2):293-297. doi: 10.1016/j.pjnns.2017.12.004. Epub 2017 Dec 14.
• [28] Immunization with rP22 induces protective immunity against Schistosoma mansoni: effects on granuloma down-modulation and cytokine production.Immunol Lett. 2011 Dec 30;141(1):123-33. doi: 10.1016/j.imlet.2011.09.003. Epub 2011 Sep 17.
• [29] P35 and P22 Toxoplasma gondii antigens abbreviate regions to diagnose acquired toxoplasmosis during pregnancy: toward single-sample assays.Clin Chem Lab Med. 2017 Mar 1;55(4):595-604. doi: 10.1515/cclm-2016-0331.
• [30] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [31] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [32] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [33] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [34] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [35] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [36] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [37] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [38] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [39] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [40] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [41] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [42] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [43] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [44] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [45] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [46] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [47] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [48] Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
• [49] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.